Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma
Latest Information Update: 08 Aug 2024
At a glance
- Drugs BNT 113 (Primary)
- Indications Anal cancer; Carcinoma; Cervical cancer; Head and neck cancer; Penile cancer; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms HARE-40
- 05 Aug 2024 According to a BioNTech media release, data from this study will be presented in at the 2024 Congress of the European Society of Medical Oncology taking place from September 13-17, 2024 in Barcelona, Spain.
- 02 Feb 2024 Status changed from active, no longer recruiting to completed.
- 02 Feb 2024 Status changed from active, no longer recruiting to completed.